NanoMuG has secured first place at the Start Cup Piemonte Valle d’Aosta 2025, the region’s leading business competition, which this year selected the top projects from more than 200 business ideas. The jury recognized the strong innovative value of our nanotechnology platform, capable of mimicking and enhancing the body’s natural defense mechanisms to revolutionize how drugs are delivered.
A bio-inspired platform that transforms drug delivery
At the core of NanoMuG is a technology based on glycosylated mucin nanoparticles, the mucosomes: a unique platform that combines natural targeting, intrinsic mucoadhesion, and the ability to protect and encapsulate both small and large therapeutic molecules.
A recognition that rewards vision, research, and technological impact
The Start Cup highlighted NanoMuG’s ability to merge scientific rigor, industrial vision, and technological transferability. Supported by the University of Turin’s incubator 2i3T, the startup was founded as an academic spin-off to turn years of research into a concrete solution for the pharmaceutical sector.
Towards a new generation of mucosal therapies
The recognition received at the Start Cup strengthens our mission: to reinvent drug delivery through a bio-inspired nanotechnology platform capable of accelerating the development of new formulations, improving therapeutic safety, and opening new opportunities for both existing and future drugs. NanoMuG now continues its path toward advanced preclinical validation, the development of partnerships with biotech, pharma, and CDMOs, and new applications in mucosal diseases.